Triple
T5981239
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Elan Pharmaceuticals |
E133121
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object |
bapineuzumab
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
|
E559467
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69c0086f45e8819098f73dd16d45ec9d |
elicitation | completed |
| NER | batch_69c04a67c3248190ba35a7121eb49672 |
ner | completed |
| NED1 | batch_69c0e42174a88190b8b40cbc7815911f |
ned_source_triple | completed |
| NED2 | batch_69c0f6a75b908190b35d13b9593cf21f |
ned_description | completed |
| NEDg | batch_69c0f602b79881909a6d971972f760b1 |
nedg | completed |
Created at: March 22, 2026, 4:04 p.m.